Alemtuzumab in the up-front setting

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 459-464

  Kaufman, Matthew ^a   Rai, Kanti R ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

11q deletion; 17p deletion; Alemtuzumab; Chronic lymphocytic leukemia; Consolidation; Miniimal residual disease

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; PROTEIN P53; PURINE DERIVATIVE; RITUXIMAB;

BONE MARROW DISEASE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LUNG ASPERGILLOSIS; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SEPTICEMIA; SIDE EFFECT; SPLEEN DISEASE; STEM CELL TRANSPLANTATION; TOXOPLASMOSIS; TREATMENT RESPONSE; TRISOMY 21; TUBERCULOSIS; VIREMIA; VIRUS INFECTION; VIRUS REACTIVATION;

EID: 44049101391     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Dyer MJ, Kelsey SM, Mackay HJ, et al. 1997. In vivo purging of residual disease in CLL with Campath-1H. Br J Haematol, 97:669-72.
2. Elter T, Borchmann P, Schultz H, et al. 2005. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia results of phase II trial. J Clin Oncol, 23:7024-31.
3. Faderl S, Thomas DA, O'Brien S, et al. 2003. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 101:3413-5.
4. Hillmen P, Skotnicki A, Robak T, et al. 2006. Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract]. J Clinc Oncol, 24(Suppl):339s. Abstract 6511.
5. Hillmen P, Skotnicki A, Robak T, et al. 2007. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol, 25:5616-23.
6. Keating MJ, Flinn I, Jain V, et al. 2002. Therapeutic role of alemtuzumab (Campath 1-H) in patients who have failed fludarabine: results of a large international study. Blood, 99:3554-61.
7. Kennedy B, Rawstron A, Carter C, et al. 2002. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 99:2245-47.
8. Lozanski G, Heerema NA, Flinn IW, et al. 2004. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103:3278-81.
9. Lundin J, Kimby E, Bjorkholm M, et al. 2002. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath 1-H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100:768-73.
10. Martin SI, Marty FM, Fiumara K, et al. 2006. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis, 43:16-24.
11. Montillo M, Tedeschi A, et al. 2006. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol, 24:2337-42.
12. Montserrat E. 2005. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease negative status as a goal. J Clin Oncol, 23:2884-5.
13. Moreton P, Kennedy B, Lucas G, et al. 2005. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol, 23:2971-79.
14. O'Brien SM, Kantarjian HM, Thomas DA, et al. 2003. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, 98:2657-63,
15. O'Brien, Keating MJ, Mocarski ES. 2006. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma, 7:125-30.
16. Osterberg A, Fassas AS, Anagnosopoulos A, et al. 1996. Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukemia. Br J Haematol, 93:151-3.
17. Osterborg A, Dyer MJ, Bunjes D, et al. 1997. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol, 15:1567-74.
18. Rai KR, Byrd JC, Peterson B, et al. 2003. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 1990. Blood, abstract 2506, 676a.
19. Rai KR, Byrd JC, Peterson BL, et al. 2002b. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease. Cancer and Leukemia Group B (CALG) Study 19901. Blood, abstract 772, 205a.
20. Rai KR, Freter CE, Mercier RJ, et al. 2002a. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol, 20:3891-7.
21. Robak T, Dmosynska A, Fetni R, et al. 2006. Incidence of genomic aberrations and associated efficacy from a phase III study alemtuzumab vs. chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (B-CLL). Blood, 108:593a (abstract 2092).
22. Stilgenbauer S, Cohner H. 2002. Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med, 347:452-3.
23. Wendtner CM, Ritgen M, Schweighoffer CD, et al. 2004. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLS). Leukemia, 18:1093-101.